Efavirenz | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Efavirenz
Health Canada Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Efavirenz

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

41 API Suppliers, 28 USDMF, 13 EU WC, 2 KDMF, 22 NDC API, 20 Listed Suppliers, $ API Reference Price

41 API Suppliers
28 USDMF
13 EU WC
2 KDMF
22 NDC API
20 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

189 FDF Dossiers, 59 FDA Orange Book, 40 Europe, 11 Canada, 59 South Africa, 20 Listed Dossiers

189 FDF Dossiers
59 FDA Orange Book
40 Europe
11 Canada
59 South Africa
20 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 400MG;300MG;300MG, CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 600MG, TABLET;ORAL - 600MG;200MG;300MG

TABLET;ORAL - 400MG;300MG;300MG
CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE;ORAL - 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 600MG
TABLET;ORAL - 600MG;200MG;300MG

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 2 Seqens, 8 DKSH, 4 Faran Shimi Pharmaceutical, 5 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 14 BASF, 10 Corel Pharma Chem, 6 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 7 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 31 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 12 Roquette, 7 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 12 Sigachi Industries, 2 The Dow Chemical Company, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

52 Coating Systems & Additives, 45 Fillers, Diluents & Binders, 28 Controlled & Modified Release, 24 Disintegrants & Superdisintegrants, 20 Thickeners and Stabilizers, 17 Granulation, 16 Lubricants & Glidants, 14 Direct Compression, 10 Topical, 9 Empty Capsules, 8 Film Formers & Plasticizers, 7 Co-Processed Excipients, 6 Taste Masking, 5 Parenteral, 5 API Stability Enhancers, 5 Coloring Agents, 5 Solubilizers, 4 Vegetarian Capsules, 4 Emulsifying Agents, 3 Rheology Modifiers, 3 Chewable & Orodispersible Aids, 1 Surfactant & Foaming Agents

52 Coating Systems & Additives
45 Fillers, Diluents & Binders
28 Controlled & Modified Release
24 Disintegrants & Superdisintegrants
20 Thickeners and Stabilizers
17 Granulation
16 Lubricants & Glidants
14 Direct Compression
10 Topical
9 Empty Capsules
8 Film Formers & Plasticizers
7 Co-Processed Excipients
6 Taste Masking
5 Parenteral
5 API Stability Enhancers
5 Coloring Agents
5 Solubilizers
4 Vegetarian Capsules
4 Emulsifying Agents
3 Rheology Modifiers
3 Chewable & Orodispersible Aids
1 Surfactant & Foaming Agents

DIGITAL CONTENT

55 NEWS #PharmaBuzz

55 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 24 Finished Drug Prices, 15 Annual Reports

3 US Medicaid Prescriptions
24 Finished Drug Prices
15 Annual Reports

MARKET PLACE

8 APIs, 5 FDF Dossiers

8 APIs
5 FDF Dossiers

PATENTS & EXCLUSIVITIES

10 US Patents, 10 Health Canada Patents

10 US Patents
10 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 USP, 5 Others

5 USP
5 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 94 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

10 All

01 6Bristol-Myers Squibb Canada

02 4Gowling Lafleur Henderson LLP

filter Patent Reset all filters

10 All

01 42101572

02 42279198

03 22332876

filter Product Reset all filters

10 All

01 10Efavirenz

filter Dosage Reset all filters

10 All

01 4Capsule

02 6Tablet

filter Exp Date Reset all filters

10 All

01 42013-07-29

02 42018-02-02

03 22019-05-24

Product Main Page

01

Bristol-Myers Squibb Canada

Efavirenz

The Generic Rx Session

Not Confirmed

Bristol-Myers Squibb Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2018-02-02

Date Granted : 2009-04-14

Brand Name : SUSTIVA

Patent Number : 2279198

Filing Date : 1998-02-02

Strength per Unit : 200 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2018-02-02

Date Granted : 2009-04-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Bristol-Myers Squibb Canada

Efavirenz

The Generic Rx Session

Not Confirmed

Bristol-Myers Squibb Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2018-02-02

Date Granted : 2009-04-14

Brand Name : SUSTIVA

Patent Number : 2279198

Filing Date : 1998-02-02

Strength per Unit : 300mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2018-02-02

Date Granted : 2009-04-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Bristol-Myers Squibb Canada

Efavirenz

The Generic Rx Session

Not Confirmed

Bristol-Myers Squibb Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2019-05-24

Date Granted : 2008-07-08

Brand Name : SUSTIVA

Patent Number : 2332876

Filing Date : 1999-05-24

Strength per Unit : 300mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2019-05-24

Date Granted : 2008-07-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Bristol-Myers Squibb Canada

Efavirenz

The Generic Rx Session

Not Confirmed

Bristol-Myers Squibb Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2018-02-02

Date Granted : 2009-04-14

Brand Name : SUSTIVA

Patent Number : 2279198

Filing Date : 1998-02-02

Strength per Unit : 600mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2018-02-02

Date Granted : 2009-04-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Bristol-Myers Squibb Canada

Efavirenz

The Generic Rx Session

Not Confirmed

Bristol-Myers Squibb Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2019-05-24

Date Granted : 2008-07-08

Brand Name : SUSTIVA

Patent Number : 2332876

Filing Date : 1999-05-24

Strength per Unit : 600mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2019-05-24

Date Granted : 2008-07-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Bristol-Myers Squibb Canada

Efavirenz

The Generic Rx Session

Not Confirmed

Bristol-Myers Squibb Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2018-02-02

Date Granted : 2009-04-14

Brand Name : SUSTIVA

Patent Number : 2279198

Filing Date : 1998-02-02

Strength per Unit : 50 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2018-02-02

Date Granted : 2009-04-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

Gowling Lafleur Henderson LLP

Efavirenz

The Generic Rx Session

Not Confirmed

Gowling Lafleur Henderson LLP

Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2013-07-29

Date Granted : 2001-08-28

Brand Name : SUSTIVA

Patent Number : 2101572

Filing Date : 1993-07-29

Strength per Unit : 50 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2013-07-29

Date Granted : 2001-08-28

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

Gowling Lafleur Henderson LLP

Efavirenz

The Generic Rx Session

Not Confirmed

Gowling Lafleur Henderson LLP

Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2013-07-29

Date Granted : 2001-08-28

Brand Name : SUSTIVA

Patent Number : 2101572

Filing Date : 1993-07-29

Strength per Unit : 200 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2013-07-29

Date Granted : 2001-08-28

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

Gowling Lafleur Henderson LLP

Efavirenz

The Generic Rx Session

Not Confirmed

Gowling Lafleur Henderson LLP

Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2013-07-29

Date Granted : 2001-08-28

Brand Name : SUSTIVA

Patent Number : 2101572

Filing Date : 1993-07-29

Strength per Unit : 300mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2013-07-29

Date Granted : 2001-08-28

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

Gowling Lafleur Henderson LLP

Efavirenz

The Generic Rx Session

Not Confirmed

Gowling Lafleur Henderson LLP

Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2013-07-29

Date Granted : 2001-08-28

Brand Name : SUSTIVA

Patent Number : 2101572

Filing Date : 1993-07-29

Strength per Unit : 600mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2013-07-29

Date Granted : 2001-08-28

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!